Simon Greaves

Simon Greaves is a high-impact Corporate Affairs leader with over 18 years of experience in delivering significant value to FTSE companies, specializing in biopharma and life sciences. He is an entrepreneurial self-starter who founded a successful political analysis business in Brussels that generated over €1 million in revenue before he turned 30. Simon is a proven English-French bilingual leader adept at driving change, nurturing talent, and enhancing performance in complex, matrixed multinational teams.

In his role, Simon focuses on developing and executing policy and communication strategies that facilitate market access and reputation management for organizations. He excels in building corporate affairs capabilities within heavily regulated sectors and has a strong track record as a skilled negotiator and influencer, collaborating with C-Suite executives to engage with high-level governmental authorities worldwide. Simon is known for leading impactful campaigns that drive measurable bottom-line benefits through stakeholder involvement.

Simon's passion lies in leveraging innovation to enhance people's health and well-being. He sees digital transformation as a key enabler for applying technology to drive healthcare innovation, fostering collaboration among stakeholders to capitalize on the current opportunities available.

Throughout his career, Simon Greaves has achieved notable milestones, including delivering a successful multinational Government Affairs strategy that safeguarded AstraZeneca from a $118 billion takeover attempt by Pfizer, creating a corporate affairs strategy for a €6 billion commercial region in Europe, focusing on market influence for cutting-edge medicines, enhancing communication capabilities, and crisis management. Simon also orchestrated a Board-approved Brexit strategy to mitigate risks related to critical medicine shortages by engaging in lobbying efforts and media interactions. Additionally, he spearheaded a strategic communication campaign, leveraging a Nature article to boost R&D productivity from a 4% to 19% success rate. Simon's early career move to Brussels to establish a EU political analysis business, which achieved substantial revenue growth in just two years, showcases his enterprising spirit and business acumen.